Database Caplus on STN, AN 1993:52043, Massaia et al, Pharmacol. Res. (1992), 26(Suppl. 2), 12-13, Jan. 1993.* |
Database Caplus on STN, AN 1991:254036, Bluth et al, “Synergistic Drugs for the treatment of bronchitis and emphysema, comprising calcium channel blockers and phosphodiesterase inhibitors”, Ger. (East), 2pp., DD 281345 A5, Aug. 8, 1990.* |
Khabar, et al. The 9th Inter. Congress of Immunology; San Francisco CA., Jul. 23-29, 1995, “Pentoxifylline Selectively Potentiates Cyclosporin a (CYA)-Mediated Suppression of Mixed Lymphocyte (MLC) Among other Immunological Functions” #5054. |
Carrier, et al. Transplantation Proceedings, 26(5): 2745-2746 (1994), “Effect of Pentoxifylline on Renal Toxicity of Cyclosporine: Preliminary Results”. |
Galdal, et al. Biochem. Pharmacology, 33(17):2723-2726 (1984), “Inhibition of the Thromboplastin Response of Endothelial Cells in Vitro”. |
Sarriá, et al. Fundam. Clin. Pharmacol., 826-33 (1994), “The nicardipineisoprenaline interaction in human and guinea-pig isolated airways”. |
Berkenboom, et al. J. of Cardiovascular Pharmacol., 18(5):761-768 (1991), “Prevention of Cyclosporine A-Induced Vascular Toxicity by Pentoxifylline”. |
Stewart, et al. Amer. J. of Clin. Oncol., 17(4):313-316 (1994), “Addition of Pentoxifylline plus Nifedipine to Chemotherapy in Patients with Cisplatin-Resistant Cancers of the Lung and Other Sites”. |
Reece, et al. Ann. Meeting of the Canadian Society of Clinical Investigation and the Royal College of Physicians and Surgeons of Canada, Sep. 11-14, 1992 “Chronic Graft-Versus-Host Disease (CGVHD) in Patients (PTS) Receiving Unrelated Donor *UD) Allogeneic Bone Marrow Transplants (ALLO BMTS) Incidence Risk Factors and Outcome”. |
Hui, et al. Chemical Abstracts AN 1988: 216076. |
Massaia, et al. Chemical Abstracts AN 19993:52043, “Cyclosporin A and dipyridamole: an effective combination against the generation of cytotixic T lymphocytes.”, Pharmacol. Res. (1992) 26(suppl. 2):12-13. |